CEOS OTC
Psykey, Inc.
1W: -15.9%
1M: -23.8%
3M: +154.2%
YTD: +103.3%
1Y: -39.9%
3Y: -81.2%
5Y: -95.8%
$0.01
+0.00 (+23.66%)
Weekly Expected Move ±15.7%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.1M
52W Range0.0006-0.0125
Volume325,000
Avg Volume136,364
Beta0.34
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Maher
Employees6
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date2006-02-14
Websitepsykeyworld.com
17 Belfield Road
Toronto, ON M9W1E8
CA
Toronto, ON M9W1E8
CA
888 376 8258
About Psykey, Inc.
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada.
Latest News
No recent news
Recent Insider Trades
No insider trades found